These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17186200)

  • 21. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whatever happened to the Norwegian Medical Need Clause? Lessons for current debates in EU pharmaceutical regulation.
    Brooks E; Geyer R
    Sociol Health Illn; 2016 May; 38(4):576-91. PubMed ID: 26564268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Assessment of the pharmaceutical expenditure in Hungary].
    Inotai A; Merész G; Kaló Z
    Acta Pharm Hung; 2010; 80(4):162-72. PubMed ID: 21404477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation of the 2011 Reimbursement Act in Poland: Desired and undesired effects of the changes in reimbursement policy.
    Kawalec P; Sagan A; Stawowczyk E; Kowalska-Bobko I; Mokrzycka A
    Health Policy; 2016 Apr; 120(4):356-61. PubMed ID: 26994865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How do patent rights affect regulatory approvals and data exclusivity rights for pharmaceuticals in the EU?
    Bogaert P; Van Keymeulen E
    Pharm Pat Anal; 2012 Sep; 1(4):393-405. PubMed ID: 24236878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative approaches to pharmaceutical price regulation in the European Union.
    Mrazek MF
    Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceutical policies in Canada: another example of federal-provincial discord.
    Anis AH
    CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prices of pharmaceutical preparations in Denmark until 1645: a study of the legislation for stipulating the consumer price of drugs].
    Kruse PR
    Theriaca; 1991 Oct; 27():3-315. PubMed ID: 11640853
    [No Abstract]   [Full Text] [Related]  

  • 31. [European ordinance on orphan drugs: changes and threats].
    Linthorst GE; Hollak CE
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Between pharmaceutical patents and European patients: is a compromise still possible?
    Garattini L; Padula A
    Expert Opin Ther Pat; 2017 Oct; 27(10):1073-1076. PubMed ID: 28671001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
    Timur A; Picone G
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?
    Ozierański P; McKee M; King L
    Health Econ Policy Law; 2012 Apr; 7(2):175-95. PubMed ID: 21819633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlling the production and distribution of drugs in communist Poland.
    Łotysz S
    Med Secoli; 2014; 26(2):537-74. PubMed ID: 26054214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of sanitary-epidemiological services in Poland in the years 1944-2014.
    Grabowski ML; Kosińska B; Knap JP
    Postepy Hig Med Dosw (Online); 2017 Nov; 71(0):915-920. PubMed ID: 29151061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Restrictions on import of drugs for personal use within the European single market.
    Mäkinen MM; Rautava PT; Forsström JJ
    Eur J Public Health; 2002 Dec; 12(4):244-8. PubMed ID: 12506498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.